Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=34417590&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates #MMPMID34417590
Corbett KS; Werner AP; Connell SO; Gagne M; Lai L; Moliva JI; Flynn B; Choi A; Koch M; Foulds KE; Andrew SF; Flebbe DR; Lamb E; Nurmukhambetova ST; Provost SJ; Bock KW; Minai M; Nagata BM; Ry AV; Flinchbaugh Z; Johnston TS; Mokhtari EB; Mudvari P; Henry AR; Laboune F; Chang B; Porto M; Wear J; Alvarado GS; Boyoglu-Barnum S; Todd JM; Bart B; Cook A; Dodson A; Pessaint L; Steingrebe K; Elbashir S; Sriparna M; Pekosz A; Andersen H; Wu K; Edwards DK; Kar S; Lewis MG; Boritz E; Moore IN; Carfi A; Suthar MS; McDermott A; Roederer M; Nason MC; Sullivan NJ; Douek DC; Graham BS; Seder RA
Nat Immunol 2021[Oct]; 22 (10): 1306-1315 PMID34417590show ga
B.1.351 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant most resistant to antibody neutralization. We demonstrate how the dose and number of immunizations influence protection. Nonhuman primates received two doses of 30 or 100 microg of Moderna's mRNA-1273 vaccine, a single immunization of 30 microg, or no vaccine. Two doses of 100 microg of mRNA-1273 induced 50% inhibitory reciprocal serum dilution neutralizing antibody titers against live SARS-CoV-2 p.Asp614Gly and B.1.351 of 3,300 and 240, respectively. Higher neutralizing responses against B.1.617.2 were also observed after two doses compared to a single dose. After challenge with B.1.351, there was ~4- to 5-log(10) reduction of viral subgenomic RNA and low to undetectable replication in bronchoalveolar lavages in the two-dose vaccine groups, with a 1-log(10) reduction in nasal swabs in the 100-microg group. These data establish that a two-dose regimen of mRNA-1273 will be critical for providing upper and lower airway protection against major variants of concern.
free
free
free
Nat+Immunol 2021 ; 22 (10): 1306-1315
